Phase I/II randomized controlled trial of autologous bone marrow-derived mesenchymal stem cell therapy for chronic stroke

AIM: To examine the safety and efficacy of mesenchymal stem cell (MSC) therapy for intracerebral haemorrhage with neurological dysfunctions for a year. METHODS: MSC were ex vivo expanded from 29 mL (17-42 mL) autologous bone marrow. Patients were randomized to have two intravenous injections of auto...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsang, Kam Sze, Ng, Chi Ping Stephanie, Zhu, Xian Lun, Wong, George Kwok Chu, Lu, Gang, Ahuja, Anil Tejbhan, Wong, Ka Sing Lawrence, Ng, Ho Keung, Poon, Wai Sang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2017
Materias:
Randomized Controlled Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583532/
https://www.ncbi.nlm.nih.gov/pubmed/28928910
http://dx.doi.org/10.4252/wjsc.v9.i8.133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583532/
https://www.ncbi.nlm.nih.gov/pubmed/28928910
http://dx.doi.org/10.4252/wjsc.v9.i8.133

Ejemplares similares